ID   NB(TU)1
AC   CVCL_3041
SY   NB(Tu)-1; NBTU1; NB(TU)1-10; NB (TU) 1-10; NB-TU-1-10; NBTU110
DR   CLO; CLO_0037082
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03470814
DR   BioSample; SAMN03470968
DR   cancercelllines; CVCL_3041
DR   Cell_Model_Passport; SIDM00579
DR   Cosmic; 1037354
DR   Cosmic; 2131596
DR   Cosmic-CLP; 1240181
DR   DepMap; ACH-002277
DR   EGA; EGAS00001000978
DR   GDSC; 1240181
DR   GEO; GSM827250
DR   GEO; GSM1670144
DR   JCRB; JCRB0154
DR   JCRB; NIHS0179
DR   LINCS_LDP; LCL-1976
DR   PharmacoDB; NBTU110_982_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_3041
DR   Wikidata; Q54907513
RX   PubMed=9378542;
RX   PubMed=15892104;
RX   PubMed=20215515;
RX   PubMed=25877200;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   Doubling time: 49 hours (PubMed=9378542).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0.86%; Native American=0.24%; East Asian, North=77.99%; East Asian, South=19.62%; South Asian=1.28%; European, North=0%; European, South=0% (PubMed=30894373).
CC   Discontinued: JCRB; NIHS0179; true.
ST   Source(s): Cosmic-CLP; JCRB; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 12
ST   D16S539: 9,11 (PubMed=25877200)
ST   D16S539: 9,11,12 (Cosmic-CLP)
ST   D16S539: 9,12 (JCRB)
ST   D18S51: 13,15
ST   D19S433: 13.2,14
ST   D21S11: 30
ST   D2S1338: 17,19
ST   D3S1358: 15
ST   D5S818: 10
ST   D7S820: 12
ST   D8S1179: 13,16
ST   FGA: 22,24
ST   Penta D: 12,14
ST   Penta E: 14,19
ST   TH01: 9
ST   TPOX: 11
ST   vWA: 14
DI   NCIt; C3270; Neuroblastoma
DI   ORDO; Orphanet_635; Neuroblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   1Y8M
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 28
//
RX   PubMed=9378542; DOI=10.1002/(SICI)1097-0215(19970917)72:6<1070::AID-IJC23>3.0.CO;2-7;
RA   Inoue A., Yokomori K., Tanabe H., Mizusawa H., Sofuni T., Hayashi Y.,
RA   Tsuchida Y., Shimatake H.;
RT   "Extensive genetic heterogeneity in the neuroblastoma cell line
RT   NB(TU)1.";
RL   Int. J. Cancer 72:1070-1077(1997).
//
RX   PubMed=15892104; DOI=10.1002/gcc.20198;
RA   Mosse Y.P., Greshock J., Margolin A.A., Naylor T., Cole K., Khazi D.,
RA   Hii G., Winter C., Shahzad S., Asziz M.U., Biegel J.A., Weber B.L.,
RA   Maris J.M.;
RT   "High-resolution detection and mapping of genomic DNA alterations in
RT   neuroblastoma.";
RL   Genes Chromosomes Cancer 43:390-403(2005).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//